University of Missouri-Kansas City Awarded Eye Disease Drug Therapy Research Grant

Share on Facebook

Researchers at the University of Missouri-Kansas City Vision Research Center have received a grant from the National Eye Institute at the National Institutes of Health, according to a news release.

 

The $1.125 million grant will go to support the development of new drug therapies for protecting the retina and optic nerve in chronic degenerative eye disease.

 

Research will be led by Peter Koulen, PhD, professor and endowed chair in vision research at the School of Medicine and director of basic research at the Vision Research Center.

 

"Degeneration or damage of the retina and the optic nerve — the nerve that connects the eye to the brain and makes vision possible — is a leading cause of loss of quality of life and productivity in the United States and worldwide," said Dr. Koulen, in the releas. "The therapy approach we're developing focuses on much-needed protection of nerve cells in the eye. The goal is to develop drug therapies that will be both preventative and therapeutic and complement existing treatment designs and rationales."

 

Related Articles on Ophthalmology:

How ASCs Can Profit From Ophthalmology

Ophthalmologist Dr. William Constad to Receive 'Man of Vision' Honor

Ophthalmologist on the Move: Dr. George Baerveldt Joins CA's NVISION Laser Eye Centers

© Copyright ASC COMMUNICATIONS 2014. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.